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Abstract
Background: Human CEACAM1 is a cell-cell adhesion molecule with multiple functions including insulin clearance in the
liver, vasculogenesis in endothelial cells, lumen formation in the mammary gland, and binding of certain human pathogens.
Principal Findings: Three genomic BAC clones containing the human CEACAM1 gene were microinjected into pronuclei of
fertilized FVB mouse oocytes. The embryos were implanted in the oviducts of pseudopregnant females and allowed to
develop to term. DNA from newborn mice was evaluated by PCR for the presence of the human CEACAM1 gene. Feces of
the PCR positive offspring screened for expression of human CEACAM1. Using this assay, one out of five PCR positive lines
was positive for human CEACAM1 expression and showed stable transmission to the F1 generation with the expected
transmission frequency (0.5) for heterozygotes. Liver, lung, intestine, kidney, mammary gland, and prostate were strongly
positive for the dual expression of both murine and human CEACAM1 and mimic that seen in human tissue. Peripheral
blood and bone marrow granulocytes stained strongly for human CEACAM1 and bound Neisseria Opa proteins similar to
that in human neutrophils.
Conclusion: These transgenic animals may serve as a model for the binding of human pathogens to human CEACAM1.
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Introduction
CEACAM1 (carcinoembryonic antigen related cell adhesion
molecule-1) is a type 1 transmembrane protein expressed on most
epithelial cells, phagocytes and activated lymphocytes [1,2]. In the
case of epithelial cells, its cell adhesion activity is associated with
diverse functions including angiogenesis [3,4], lumen formation
[5,6,7] and the binding of extracellular pathogens [8]. In the case
of neutrophils, it may play a role in the binding of neutrophils to
activated endothelium and extravasation into inflamed tissues
[9,10], and similar to epithelial cells, may bind extracellular
pathogens [8,11,12]. In the case of activated lymphocytes, it serves
as an inhibitory molecule, controlling the strength and duration of
the immune response [2]. CEACAM1 is a critical molecule well
situated to play a communication role between epithelial cells, that
represent the first barrier to infection, and immune cells that
control infections that disrupt the epithelial barrier. Thus,
pathogens that bind to CEACAM1 may interfere with its normal
function, namely maintenance of communication between these
two barriers to infection.
CEACAM1 has multiple splice forms that are differentially
expressed between epithelial and immune cells. The so-called
‘‘long form’’ has a cytoplasmic domain containing two ITIMs
(immunoreceptor tyrosine-based activation motifs) that, when
phosphorylated, may bind Src homology 2 domain-containing
tyrosine phosphatases SHP1 and SHP2 [13] to convey inhibitory
signals to the T-Cell receptor [14,15,16], B-Cell receptor [17], and
epithelial growth factor receptor [18]. The long form also has a b-
catenin binding site [19] and a filamin A binding site [20]. The so-
called ‘‘short form’’ lacks the ITIMs, but has the ability, like the
long form, to bind actin, calmodulin, and annexin II [21]. These
activities indicate a strong association of CEACAM1 with actin
cytoskeleton [7,21,22].
Among the human extracellular pathogens known to bind to
human CEACAM1, Neisseria gonorrhoeae and Neisseria meningitidis
have been shown to bind via the expression of their Opa (colony
opacity-associated) proteins leading to adherence and invasion into
epithelial cells [11,23] and engulfment by neutrophils [8,23,24], as
well as suppression of the T-lymphocyte response [25] and killing
human B cells [26] effects that presumably inhibit antibody
production. As mentioned above, the inhibitory activity is
mediated by phosphorylation of the ITIMs on the long form of
CEACAM1 and subsequent recruitment of SHP1/2 [13,27] that
can disrupt phosphorylation of important receptors, including the
insulin receptor [28], EGFR [29], TCR [14,15], BCR [17], and
TLR2 [30]. In the case of Neisseria gonorrhoeae, neutrophils, due to
their high levels of CEACAM1 expression, are a major target for
spreading the infection in the urogenital tract. A major limitation
to studying these interactions in vivo has been the lack of an animal
model, since murine CEACAM1 is not a receptor for these human
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generated a human CEACAM1 transgenic mouse that faithfully
expresses human CEACAM1 in the expected tissues, including
neutrophils. We demonstrate here that the neutrophils from the
transgenic mice as well as human neutrophils bind gonococcal
Opa52 protein expressed on E. coli. Thus, these mice should serve
as an appropriate animal model at least for studying some aspects
of the human pathogenesis of Neisseria gonorrhoeae infections.
Materials and Methods
Growth and isolation of Bacterial Artificial Chromosome
(BAC)
Three BAC clones were purchased from Invitrogen. The DNA
was cloned into the EcoRI sites of pBACe3.6 vector and
transformed into DH10B
TM E. coli. The vector contains a
chloramphenicol resistance gene as the selectable marker. The
BAC clone numbers and maps are given below: BAC#2:
catalog#96012, Clone ID: 2023G5 Collection: BAC Human
CTD, 214 kb, from 47,526867 to 47,741809, map: http://www.
ncbi.nlm.nih.gov/projects/mapview/maps.cgi?TAXID=9606&
CHR=19&MAPS=ideogr%2Ccntg-%2CugHs%2Cgenes&BEG=
47526867&END=47741809&thmb=on BAC#3 catalog#96012,
Clone ID: 2016N11. Collection: BAC Human CTD, 138 kb
from 47,650836 to 47,788904, map: http://www.ncbi.nlm.nih.
gov/projects/mapview/maps.cgi?TAXID=9606&CHR=19&MAPS
=ideogr%2Ccntg-%2CugHs%2Cgenes&BEG=47650836&END=
47788904&thmb=on BAC#5 catalog#96012, Clone ID: 2526I10
Collection: BAC Human CTD, 211 kb from 47,665,525 to
47,877001, map: http://www.ncbi.nlm.nih.gov/projects/mapview/
maps.cgi?TAXID=9606&CHR=19&MAPS=ideogr%2Ccntg-%
2CugHs%2Cgenes&BEG=47665525&END=47877001&thmb=on
The DNA of the BAC clones was extracted with Nucleobond
PC 2000 EF kit (Macherey-Nagel, Du ¨ren Germany) according to
the manufacturer’s protocol. DNA pellets were dissolved in
endotoxin-free water overnight at room temperature, and then
used for microinjection.
Chromosomal integration site analysis
Murine bone marrow cells were collected from femurs (see later
section in Methods) and treated with colcemid (6 ml/mL in 0.075
M KCl) for 2 hours. The cells were fixed using Carnoy’s fixative
(3:1; methanol:acetic acid), dropped onto non-silanized slides, and
air-dried. The slides were baked at 60uC for 12 hours and aged at
room temperature for 72 hours. Prior to banding cells were aged
at 90uC for 15 minutes. Metaphases were GTG banded and
photographed with the BandView imaging system from Applied
Spectral Imaging (ASI). Upon completion of the GTG analysis,
the slide was de-oiled in Americlear. Slides were de-stained in
methanol for 5 minutes and rehydrated in an ethanol series: 100%,
80%, and 70% ethanol. Subsequently, the slides were post-fixed in
1% formaldehyde/1XPBS/50mM MgCl2 for 2 minutes at room
temperature, washed in 1x PBS for 5 minutes and dehydrated in
70%, 80%, and 100% ethanol series. Once the slides were air-
dried, they were denatured in 70% formamide/2x SSC at 72uC
for 30 seconds and immediately placed in cold 70%, 80%, and
100% ethanol and air-dried. Denatured mouse SkyPaint probe
(10 ml, Applied Spectral Imaging) was applied to each slide,
covered with a glass coverslip and sealed with rubber cement.
Slides were transferred to a humidified chamber and placed in a
37uC incubator for 48 hours. Post-washes and detection was done
following ASI SKY protocol. SKY metaphases were captured and
analyzed with the SkyVision spectral imaging system (Applied
Spectral Imaging).
CEACAM1 BAC2 DNA was used as a probe. Three nick
reactions were prepared using digoxigenin-dUTP. Reactions were
combined for precipitation and re-suspended in 10 mlo f1 0m M
Tris buffer pH 8.5 for hybridization. The probe was hybridized to
a human male metaphase to check for probe intensity and correct
integration site. The probe (100 ng) was combined with 9 mL
hybridization buffer, co-denatured on an 80u hotplate for 5
minutes and incubated overnight at 37uC in a humidified
chamber. Post-wash consisted of 50% formamide/2x SSC at
45uC for 15 minutes, 2x SSC at 37uC for 8 minutes and 1x PBD at
room temperature for 2 minutes. Probe was detected with
rhodamine anti-digoxigenin and following SKY imaging, the slide
was placed in 1x PBD for coverslip removal and immersed in
room temperature 2x SSC for 1 hour to remove the SKY probe.
After SSC treatment, slides were dehydrated and co-denatured for
3 minutes. Hybridization and post-wash were run as described
above. Bone marrow preparations from a wild type mouse were
used as a negative control and normal human male preparations
were used as a positive control. Total murine bone marrow cells
were prepared as described in a later section in Methods. Male
bone marrow cells were discard tissue from the City of Hope bone
marrow transplantation unit.
Growth and FITC labeling of Opa52 E. coli and vector
control E.coli
E. coli Top10 containing pTrc99A (Amp) vector only or
pTrc99A vector with an IPTG-inducible opa52 gene were a kind
gift from Dr. Scott Gray-Owen (University of Toronto, Canada).
Frozen stocks were streaked on a LB plate containing 100 mg
Ampicillin, and incubated at 37uC overnight. After 24 h, a single
colony was picked and streaked on a LB/Ampicillin plate
containing 0.1 mM IPTG, and incubated at 37uC overnight.
FITC was prepared at a final concentration of 1 mg/ml in
50 mM carbonate, 150 mM NaCl buffer (pH 9.2). Bacteria were
collected in 1 ml PBS/Mg/Ca and re-suspended by gently
pipetting and pelleted at 3000 rpm for 3 min. After removal of
the supernatant, the bacteria were re-suspended in 500 ml of FITC
solution and incubated at room temperature with gentle shaking in
the dark for 30 min. After washing (56) the bacteria were re-
suspended in PBS/Mg/Ca with 1% BSA to quench remaining
FITC. The labeled bacteria were diluted to a working ratio of 30
bacteria to 1 neutrophil.
Pronuclear microinjection of fertilized mouse oocytes
All experiments involving live animals were conducted with the
approval of the City of Hope institutional animal care and use
committee. Mice used in the derivation of transgenic mice were
maintained on a 14 hr light/10 hr dark cycle. Female mice (FVB/
NJ, Jackson Laboratories) were superovulated with 5 IU of
pregnant-mare serum-gonadotropin (National Hormone and
Peptide Program, UCLA, Los Angeles, CA) followed 48 hours
later by 5 IU of human-chorionic gonadotropin (Sigma-Aldrich,
St. Louis MO) and mating to fertile FVB/NJ males. Fertilized
oocytes were collected ,12 to 14 hours after the middle of the
dark cycle, and treated briefly with bovine hyaluronidase in M2
medium to remove the cumulus cells. Immediately prior to
microinjection the purified BAC DNA was diluted to a
concentration of 3 ng/mL in 1 mM Tris-HCl (pH 8.0), 0.1 mM
EDTA, 100 mM NaCl containing 30 mM spermine/70 mM
spermidine [31]. The BAC DNA solution was microinjected into
the pronuclei of fertilized oocytes using standard techniques, and
the manipulated oocytes were transferred surgically into the
oviducts of 0.5 dpc pseudo-pregnant recipient female mice and
allowed to develop to full term.
CEACAM1 Transgenic Mice
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10067PCR analysis to screen positive pups
The initial screening of founder mice for the human CEACAM1
transgene was carried out by PCR analysis on mouse tail DNA.
Briefly, tail samples (1–3 mm) were digested in 0.25 mL 0.4 N
NaOH at 95uC for 10 to 15 min until tails were fully digested.
Followed by adding 0.375 mL neutralization buffer (0.5 M Tris
pH 8.0+20 mM EDTA). Digests were then diluted 10-fold. PCR
were then performed by using Bio-Rad iCycler PCR (Bio-Rad
Laboratory, Hercules, CA) with 2X fideliTaq PCR master mix
(USB, Cleveland, Ohio). Two mL of diluted tail DNA was added
into a final 20 mL volume reaction. The sense strand primer 59-
CACCATGCCCAGCTAATTTT-39 and antisense strand primer
59-GTGGTCTGTTGCTCCCAGAT-39 only target the human
CEACAM1 gene. The amplified product is 260 bp. The amplifi-
cation parameters were initiated at 95uC for 5 min, then 95u C for
30 s, 53uC for 30 s, and 72uC for 30 s for 35 cycles, followed by
7 min at 72uC for the final extension. The primer sets for the
mouse CEACAM1 gene are: sense 59-ATGAACAGTGAGG-
CAGTCCC-39 and antisense 59-CAGAGGAAGAGTGTC-
CAGGC-39. The amplification parameters were initiated at
95uC for 5 min, then 95u C for 30 s, 55uC for 30 s, and 72uC
for 30 s for 35 cycles, followed by 7 min at 72uC for the final
extension. The final product length is 155 bp.
Western blot analysis
Eight weeks old F2 pups (one human CEACAM1 gene positive
and one negative by PCR) were euthanized by CO2 inhalation.
Liver, heart, lung, brain, kidney, spleen, small intestine (ileum),
and neutrophil (from peripheral blood) or fecal pellets were
homogenized and lysed in 1% NP-40 lysis buffer. Cell lysates
were incubated on ice for 30 min, followed by centrifugation for
30 min at 4uC at 14000 rpm. Total protein (50 mg) was separated
by sodium dodecyl sulfate-gel polyacrylamide electrophoresis,
transferred to nitrocellulose membranes and probed with either
anti-murine CEACAM1 mAb CC1 (1 mg/mL, kind gift from Dr.
Kathryn Holmes, University of Colorado health Sciences,
Denver, CO) and anti-b-actin antibody (1 mg/mL, Abcam,
Cambridge, UK) antibody or anti-human CEACAM1 mAb
T84.1 (1 mg/mL) [32]. Signals were detected on the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE,
USA).
Immunohistochemistry
Mice were euthanized by CO2 inhalation. Tissues were
collected and fixed in 4% paraformaldehyde overnight. Immu-
nohistochemical staining was performed on 5 mmt h i c ks e c t i o n s
prepared from formalin fixed, paraffin-embedded blocks. Sec-
tions were deparaffinized in xylene and rehydrated in a graded
alcohol series. Slides were quenched in 3% hydrogen peroxide,
steamed for antigen retrieval in DIVA/citrate buffer (pH 6.0)
(BIOCARE ref; DV2004MX) for 20 minutes, and incubated in
Rodent block (BIOCARE MM HRP- Polymer Kit ref:
MM510G) for 30 minutes. The slides were incubated overnight
at 4uC with either CC1 1:250 (8 mg/mL) or T84.1 mAbs at a
1:250 dilution (15 mg/mL). The following day, slides were
washed, incubated in Mouse Polymer-HRP (BIOCARE MM
HRP- KIT ref: MM510G) for 20 minutes, and treated with the
chromogen diaminobenzidine tetrahydrochloride (DAB), coun-
terstained with hematoxylin, dehydrated through grades of
alcohols and xylenes and mounted with permanent mounting
Figure 1. Transgenic mouse screening. A. PCR screening for CEACAM1 expression. Pups 1 to 12 were born after pronuclear microinjection of
BAC2. Founders 1, 6 and 12 were positive using CEACAM1 primers. B. Western blots of feces using anti-human CEACAM1 mAb demonstrated that
BAC2 founders 1, 6 and 12 expressed human CEACAM1 in their gastrointestinal tracts. C. PCR analysis of the F1 generation from founder 12. About
50% of the pups were positive (left side) for human CEACAM1 and 100% positive for murine CEACAM1 (right side). D. Western blot analysis of feces
using anti-human CEACAM1 mAb. Pups 7, 8, 12, 13, 14, and 18 from founder BAC2-12 were positive. Most fecal samples were collected in the
morning (no label) or in the evening (7P, 8P) to determine if time of collection affected the analysis.
doi:10.1371/journal.pone.0010067.g001
CEACAM1 Transgenic Mice
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Richmond, IL), fixed in methanol for 15 sec and stained as
above. Mouse anti-human IgG1 (eBioscience, San Diego, CA)
was used as an isotype control.
Preparation of bone marrow cells and spleen cells and
isolation of neutrophils
T r a n s g e n i ca n dw i l dt y p eF V Bm i c e ,b o r nw i t h i nt h es a m e
litter, were euthanized by CO2 inhalation. The bone marrow
cells were flushed from femurs and tibias by using a 23-gauge
needle with 10 mL of cold PBS. Single cell suspensions were
prepared by flushing the cell solution twice through a 22-gauge
needle and passing the cell solution through a sterile 40-mm
nylon mesh. Spleens were removed aseptically, injected with
2 mg/mL of collagenase D and 20 mg/mL of DNase I (Roche
Diagnostics, Mannheim, Germany) in Hanks solution, minced,
incubated for 30 min at 37uC under 5% CO2, and teased
through a 40 mm nylon mesh. Red blood cells in bone marrow
cells and spleen cells were lysed twice using Red Blood Cell
Lysing Buffer Hybri-Max (Sigma-Aldrich, Saint Louis, MO
63103). Cells were washed twice with RPMI-1640 medium and
subsequently suspended in RPMI-1640 culture medium con-
taining 10% FBS and antibiotics. Cell viability was determined
by trypan blue dye exclusion.
Mouse Gr-1
+ granulocytes from bone marrow were positively
isolated using Anti-Ly-6G MicroBead Kit according to the
manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach,
Germany). Human neutrophils were isolated from discarded
blood. This study was approved by the Institutional Human
Subject’s Review Board (City of Hope National Medical Center).
Neutrophils were isolated by centrifugation over Ficoll-Paque Plus
(GE Healthcare Biosciences, Pittsburgh, PA, USA) density
gradient. Cell purities were determined by forward light-scatter/
side light-scatter gating of cells stained with PerCP-Cy5.5-
conjugated anti-CD16 mAb using a flow cytometer (FACSCan-
to
TM II, BD Biosciences) and neutrophil purity was more than
95% [33].
Neutrophil binding assay
Neutrophils from mice or human were suspended at
1610
6 cells/mL in RPMI-1640 medium. Degranulation was
induced by adding fMLF (Sigma-Aldrich, Saint Louis, MO
63103) to a final concentration of 100 nM followed by incubation
at 37uC for 30 min. FITC-labeled E. coli (30610
6 cells/mL) with
either Opa52 or vector control were added to neutrophils
(neutrophil/bacteria; 1/30) and incubated at 37uC for 60 min.
Infection was arrested by washing the neutrophils with PBS three
times.
Confocal microscopy
Neutrophils were fixed in 4% paraformaldehyde with 50 mM
HEPES buffer for 20 min at room temperature, followed by
15 min of 0.1% triton X-100, and 15 min of 0.2% BSA in PBS.
Anti-human CEACAM1 mAb T84.1 was then added to the fixed
cells at a final concentration of 1 mg/mL for 1 hour. After 3
washes with PBS, goat anti-mouse Alexa 555-conjugated antibody
(Invitrogen, Eugene, OR) was added at the concentration of 2 mg/
mL for another 30 min followed by 3 washes with PBS. Stained
cells were plated on glass slides with Hard Set mounting medium
and counterstained with DAPI from Vector Laboratories Inc
(Burlingame, CA 94010, USA). Confocal microscopy was
performed on a Zeiss Model 310 (Oberkochen, Germany) confocal
microscope.
Flow cytometry analyses
Single cell suspensions from bone marrow or spleen from
transgenic or wild-type mice were blocked by anti-mouse CD16/
32 antibody (Clone: 93, Biolegend, San Diego, CA 92121), and
Figure 2. Chromosomal location of human CEACAM1 gene in
transgenic mice. A. Human chromosomal spread showing hybridiza-
tion of human CEACAM1 gene probe to chromosome 19 (arrows). B.
Murine chromosomal spread of the transgenic mice. C. Hybridization of
human CEACAM1 gene probe to the murine chromosomal spread,
counterstained with DAPI. D. Painting of the murine chromosomal
spread from the transgenic mouse. Chromosome 11 is labeled,
demonstrating a single integration site on one chromosome
(heterozygous).
doi:10.1371/journal.pone.0010067.g002
Figure 3. CEACAM1 mRNA isoform expression in BAC2-12
transgenic mouse liver, kidney and small intestine. A. RT-PCR
analysis for CEACAM1 isoforms in transgenic (1–3) or wild type mice (4–
6) in liver (1, 4), kidney (2, 5), and small intestine (3, 6). B. RT-PCR
analysis for Ceacam1 isoforms in transgenic (7–9) or wild type mice (10–
12) in liver (7,10), kidney (8,11), and small intestine (9,12).
doi:10.1371/journal.pone.0010067.g003
CEACAM1 Transgenic Mice
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Biolegend, San Diego, CA 92121) or anti-human CEACAM1-PE
(Clone: 283340, R&D Systems Inc, Minneapolis, MN 55413). The
bone marrow cells were counter stained with anti-Gr-1-APC
(Clone: RB6-8C5) and anti-CD11b-APC-Cy7 (Clone: M1/70, BD
Biosciences, San Jose, CA 95131) to identify neutrophils, and the
spleen cells were counter stained with anti-CD3-FITC (Clone:
17A2) and anti-B220-APC (Clone: RA3-6B2, BD Biosciences, San
Jose, CA 95131) to identify B and T cells. The cell surface
expression of murine CEACAM1 and human CEACAM1 was
analyzed on FACSCanto
TM II (Becton Dickinson) with Flowjo
software (Becton Dickinson).
Single cell suspensions (1610
6/mL) from spleen from transgenic
or wild-type mice were cultured in a 24-well plate for 72 hours in
the absence or presence of 1 mg/ml plate-bound anti-CD3 mAb
(145-2C11) and 2 mg/ml soluble anti-CD28 (37.51; BD Pharmin-
gen). Cells were harvested, stained and analyzed as above methods
by FACS.
Reverse transcriptase PCR
Total RNA was isolated from transgenic mouse liver, kidney
and small intestine by using TrizolH method (GIBCO-BRL/
Invitrogen Corp., Carlsbad, CA). Briefly, samples were homoge-
nized in 800 ı `L TrizolH (GIBCO-BRL/Invitrogen Corp.,
Figure 4. Immunohistochemistry staining for human and murine CEACAM1 in BAC2-12 transgenic and wild type mice. Heart (A–C),
small intestine (D–F), kidney (G–I), and liver (J–L) in transgenic (A, B, D, E, G, H, J, K) and wild type mice (C, F, I, L) by anti-murine CEACAM1 mAb
(CC1) (A, D, G, J, C, F, I, L) or anti-human CEACAM1 mAb (T84.1) (B, E, H, K). Mag. 50X.
doi:10.1371/journal.pone.0010067.g004
Figure 5. Immunohistochemistry staining for human and murine CEACAM1 in kidney and liver of BAC2-12 transgenic and wild type
mice. A. Wild type mouse kidney. B. Transgenic mouse kidney. C. Transgenic mouse kidney with isotype control antibody. D. Wild type mouse liver.
E. Transgenic mouse liver. F. Transgenic mouse liver with isotype control antibody. Note that human CEACAM1 expression is higher than murine
CEACAM1 in transgenic mouse kidney. However, in the liver, murine and human CEACAM1 expression in transgenic mice was similar. Bowman’s
capsule in the kidney is indicated by an arrow (B). Mag. 200X.
doi:10.1371/journal.pone.0010067.g005
CEACAM1 Transgenic Mice
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After centrifugation at 4uC at 14,000 rpm for 15 min, the top layer
was transferred to a clean microcentrifuge tube and 400 ı `L of 2-
propanol was added, incubated at room temperature for 20 min
and centrifuged at 14,000 rpm for 10 min at 4uC. Total RNA was
washed in 75% ice-cold ethanol once and after 5 min was
centrifuged at 14,000 rpm at 4uC. RNA pellets were air dried and
dissolved in 50 ı `L RNase-free water. Complementary DNA
(cDNA) was prepared using the OmniscriptH reverse transcription
system (Qiagen, Inc., Valencia, CA) according to the manufac-
turer’s protocol. The reverse transcription system contains oligo
primers, RNase inhibitor, MMLV reverse transcriptase, dNTP
mix, buffer and 3 ı `g total RNA in a final volume of 20 ı `L. The
reaction mixture was incubated at 42uC for 1 h. CEACAM1
isoforms were detected by PCR on a Bio-Rad iCycler PCR (Bio-
Rad Laboratory, Hercules, CA) with 2X fideliTaq PCR master
mix (USB, Cleveland, Ohio). cDNA (5 ml) was added to a final
25 mL volume reaction. The sense strand primer 59-AACGT-
CACCCAGAATGAC-39 and antisense strand primer 59-CTCAG-
GACCACTCCAATGA-39 target human CEACAM1 gene. The
amplified products are 1118 bp (4L), 1066 bp (4S), 831 bp (3L),
779 bp (3S). The amplification parameters were initiated at 95uC
for 5 min, then 95u C for 30 s, 55uC for 90 s, and 72uC for 30 s
for 38 cycles, followed by 7 min at 72uC for the final extension.
For mouse CEACAM1, the sense strand primer 59-GA-
CTCTGTCGACGACATGGAGCTGGCCTCAGCACATC-39
and antisense strand primer 59-GACTCTATCGATTCACTTC-
TTTTTTACTTCTGAATAAAC-39 were used to PCR amplify
the murine Ceacam1 cDNAs. The four RT-PCR amplified
products for murine Ceacam1 correspond to the 4L, 4S, 2L and
2S mRNA splice isoforms. The amplification parameters were
same as above.
Results
Generation of human CEACAM1 transgenic mice
Three BAC clones containing the human CEACAM1 gene were
microinjected into the pronuclei of fertilized oocytes of FVB N/J
Figure 6. Immunohistochemistry staining for murine and human CEACAM1 in the mammary and prostate glands of BAC2-12
transgenic mice. A. Murine CEACAM1 expression in the mammary gland (Mag 50X). B and C. Human CEACAM1 expression in the mammary gland
(Mag 50X and 200X, respectively). D. Murine CEACAM1 expression in the prostate gland (Mag 50X). E and F. Human CEACAM1 expression in the
prostate gland (Mag 50X and 200X, respectively).
doi:10.1371/journal.pone.0010067.g006
CEACAM1 Transgenic Mice
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BAC5 clones. BAC2Clone (214 kb) covered a large region
proximal to human CEACAM1 on chromosome 19, and two
other BAC clones (BAC3 and BAC5; 138, and 211 kb,
respectively) covered shorter regions flanking the human CEA-
CAM1 gene. Although litters were obtained from mice fertilized
with all three microinjections, only those from BAC2 and BAC5
transmitted the germline gene to their offspring (Fig. 1A and
data not shown), and only those from BAC2 exhibited
expression of the huCEACAM1 protein in their feces (Fig. 1B).
Since CEACAM1 is heavily expressed in the GI tract, from the
liver throughout the small and large intestine, and is shed into the
lumen of the gut like CEA [34], we used its detection in the feces
as an early diagnostic test for protein expression. As can be seen in
Fig. 1B, both murine and human CEACAM1 were detected in
the feces of the founders. Only the offspring from founder 12
(BAC2) expressed the transgene. As expected, roughly 50% of the
pups were positive for human CEACAM1 by both PCR analysis of
tail samples (Fig. 1C) and western blot analysis of fecal samples
(Fig. 1D) of the F1 generation from founder 12 (BAC2). Further
breeding of the BAC2-12 transgenic mice demonstrated transmis-
sion of an expressed CEACAM1 transgene from the F1 to F2
generation at the expected (,0.5) frequency for heterozygotes. No
attempt was made to breed the BAC2-12 line to homozygosity at
this stage of the study. Expression of the human CEACAM1
transgene was not detected in any of the BAC5 founders or their
F1 offspring. Given the small number of litters obtained from each
microinjection, it was not feasible for us to evaluate the success rate
in terms of stable integration and expression of the various BAC
clones.
The chromosomal insertion point for the BAC clone is random
in transgenic animals produced by pronuclear microinjection.
Using human specific probes for CEACAM1, we were able to
demonstrate that the human gene is on chromosome 19 of human
cells (Fig. 2A), as expected, and the BAC2 clone containing the
human CEACAM1 gene was on chromosome 11 of the transgenic
mice (Fig. 2C–D). Although we did not confirm the location of
the endogenous murine Ceacam1 gene, it has been reported to be
on chromosome 7 [35,36]. Thus, the murine Ceacam1 and human
CEACAM1 genes are on different chromosomes of the transgenic
mice. Since mRNA from the human CEACAM1 can be
alternatively spliced, it was also important to determine if the
expected splice forms were present. For this analysis, RNA was
isolated from BAC2-12 transgenic mouse liver, kidney and small
intestine and analyzed by PCR using specific primers for the major
splice forms expected in human CEACAM1. As seen in Fig. 3A,
transgenic mouse liver expressed human CEACAM1-4S and -3S
isoforms, while transgenic kidney and small intestine expressed the
-4L and -3L isoforms. Analysis of the endogenous expression of
murine CEACAM1 isoforms revealed the -4S and -2S isoforms in
Figure 7. Expression levels of murine and human CEACAM1 on bone marrow neutrophils of BAC2-12 transgenic and wild type
mice. Single cell suspensions of bone marrow from TG or WT mice were stained with either anti-murine CEACAM1-PE or anti-human CEACAM1-PE
and co-stained with anti-Gr-1-APC or anti-CD11b-APC-Cy7. Histograms on the right are from gated cells as shown. Results shown are representative
of three independent experiments with similar results.
doi:10.1371/journal.pone.0010067.g007
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isoform (Fig. 3B). Since mice express a highly homologous second
allele, namely CEACAM2, mainly expressed in the testes and
kidney, we cannot be sure if the kidney PCR products are from
murine CEACAM1 or CEACAM2. The differences in tissue
specific CEACAM1 isoform expression between mouse and man
has been previously described [37,38].
Tissue expression patterns of huCEACAM1 in transgenic
animals
Having obtained successful germline transmission of the human
CEACAM1 gene and CEACAM1 protein expression in the BAC2-
12 line of mice, we analyzed tissues from the transgenic mice by
immunohistochemical staining to determine if expression of the
human and murine genes was similar. First we analyzed heart as a
negative tissue to eliminate the possibility that inappropriate
expression occurred. Neither murine nor human CEACAM1 was
expressed in the hearts of BAC2-12 transgenic mice, and wild type
FVB mouse heart is shown as an additional control (Fig. 4A–C).
Three tissues that exhibit high expression of CEACAM1 in both
mouse and human are the intestine, kidney, and liver. As seen in
Fig. 4D–F, the expression of human CEACAM1 is similar to
murine CEACAM1 in the small intestine in terms of distribution
and intensity. As expected, both the murine and human
CEACAM1 are expressed on on the luminal surface of intestinal
epithelial cells. In the case of the kidney, the expression of human
CEACAM1 is noticeably higher than the expression of murine
CEACAM1 (compare Fig. 4H to Fig. 4G, transgenic, and
Fig. 4I, wild type FVB). This difference may be explained by the
fact that mice have two Ceacam genes (Ceacam1 and Ceacam2) that
are differentially expressed in the kidney [35,37], while humans
have a single CEACAM1 gene. Thus, the expression of the human
gene in the kidney may reflect the combined expression of the two
genes in mouse; however, the anti-murine CEACAM1 antibody
used here does not detect murine CEACAM2. The reason for the
differential expression of the two mouse genes in the kidney is
unexplained, but may reflect a role for the kidney in insulin
clearance (see below). In the case of the liver, the staining pattern
for murine and human CEACAM1 in the transgenic animals is
identical (Fig. 4J–K). The pattern shows highest expression
around the portal triads with decreased expression around the
portal artery. This may reflect the known function of CEACAM1
in effecting insulin clearance [39]. The observed CEACAM1
expression pattern follows the entrance of blood from the portal
circulation and exit via the portal artery. The staining pattern for
the murine CEACAM1 of wild type mice liver (Fig. 4L) is similar
but less intense. Further quantitative studies are required to
determine if there is a real difference in degree of expression of the
endogenous murine Ceacam1 gene between the wild type and
transgenic animals.
The high expression of CEACAM1 in kidney and liver was
examined at higher magnification. As seen in Fig. 5A–B, the
Figure 8. Immunohistochemistry staining of blood neutrophils from BAC2-12 transgenic and wild type mice. A. Transgenic mouse
blood neutrophils stained with anti-human CEACAM1 antibody. Mag. 200X (inset photo enlarged 4X). B. Wild type mouse blood neutrophils stained
with anti-human CEACAM1. Mag. 200X. C. Transgenic mice blood neutrophils stained with anti-mouse CEACAM1. Mag. 200X (inset photo enlarged
4X). D. Human neutrophils stained with anti-human CEACAM1. Mag. 200X (inset photo enlarged 4X).
doi:10.1371/journal.pone.0010067.g008
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CEACAM1, but more intense. The pattern is consistent with the
highest levels of expression in proximal tubules (less open lumen)
and the lowest in distal tubules (more open lumen). In all cases the
staining is on the luminal surface of the renal tubules. CEACAM1
is also expressed on the luminal surface of epithelial cells of the
Bowman’s capsules surrounding the glomeruli in the kidney
(arrow, Fig. 5B). In the case of the liver, the expression pattern of
both murine and human CEACAM1 in the transgenic animals is
confined to the bile canaluculi (Fig. 5D–E). This expression
pattern has been described previously [40] and suggests the
possibility that the mechanism of insulin clearance by CEACAM1
[39] may be related to the function of bile canaliculi.
The consistent luminal expression of CEACAM1 on epithelial
cells supports the hypothesis that CEACAM1 plays a role in lumen
formation in several tissues [5,6,7]. This role has been documented
in mammary epithelial cells grown in either a 3D culture [5,6,7] or
in humanized mammary fat pads in NOD/SCID mice [41,42].
CEACAM1 is also expressed on the luminal surface of prostate
glands [43], and like its expression in the mammary gland, is
down-regulated in cancer [44]. As a first step in using these
transgenic animals as a model for mammary and prostate cancer
we examined its expression in these tissues. In the case of the
mammary gland, it was necessary to study pregnant females, since
the mammary gland is minimally developed in non-pregnant
females. As shown in Fig. 6A–C, there was strong luminal
expression of both murine and human CEACAM1 in the
mammary glands of pregnant transgenic mice. There was also
evidence for cytoplasmic expression, perhaps indicating active
transport of CEACAM1 from the site of synthesis to the lumen.
Similar results were seen for the prostate glands of male human
CEACAM1 transgenic mice (Fig. 6 D–F). These results suggest
that these mice may be an appropriate model for studying the role
of human CEACAM1 in tumorigenesis within these organs.
Binding of E. coli-Opa52 by neutrophils
Another potential use of human CEACAM1 transgenic mice is to
study pathogenesis where CEACAM1 functions as the pathogen
receptor. The situation is especially critical in the case of Neisseria
gonorrhoeae infections where there is a pressing need for the
development of a vaccine [2]. Since the high expression of
CEACAM1 on neutrophils plays an important role in its
pathogenesis, we determined the expression levels of huCEA-
CAM1 on neutrophils isolated from the bone marrow and blood
of the transgenic animals. As shown in Fig. 7, the expression of
murine and human CEACAM1 in the transgenic animals was
strong. As shown in Fig. 8(A–C), the staining of murine and
human CEACAM1 was strong for neutrophils in blood smears
taken from the human CEACAM1+/2 transgenic animals, while
staining for human CEACAM1 was negative for a CEACAM12/
2 littermate. For purposes of comparison, neutrophils from a
human blood smear were stained (Fig. 8D). Notably, human
neutrophils stain more intensely than those from the transgenic
animals, suggesting a possible effect of an expression difference
between the species. In addition, we examined the expression of
human CEACAM1 in the spleen of transgenic animals. Based on
cell surface staining, there was no expression on T-cells and
significant expression on B-cells (Fig. 9A). Consistent with these
results, CEACAM1 has been shown to be inducible on both
murine [45] and human T-cells [14]. The expression of
CEACAM1 on murine [46] and human [17,47] B-cells has been
previously reported. Activation of splenocytes from transgenic
animals by anti-CD3/28 antibodies for three days revealed
increased expression of murine, but not human CEACAM1 in
T-cells (Fig. 9B). B-cell expression of murine and human
CEACAM1 is shown for comparison.
Having demonstrated expression of human CEACAM1 on the
neutrophils of the transgenic animals, it was important to
demonstrate that they could bind Opa proteins, the requisite
Neisseria gonorrhoeae ligand for human CEACAM1 [8]. For this
analysis, we utilized E. coli expressing recombinant Opa52 protein.
As shown in Fig. 10, primed neutrophils from transgenic animals
were able to bind E.coli-Opa52 much greater than E. coli-vector
control. Controls included binding of the parental (Opa-) strain on
wild type neutrophils and Opa52-expressing bacteria binding to
human neutrophils. These results suggest that the neutrophils in
the transgenic animals may mimic the behavior of human
neutrophils towards binding of Neisseria pathogens.
Discussion
The generation of human CEACAM1 transgenic mice is an
important model to demonstrate equivalence in function of the
murine and human gene orthologs. Since pathogens that utilize
human CEACAM1 as their receptor do not recognize murine
CEACAM1, such a model is essential to study their pathogenesis.
Furthermore, in order to demonstrate that CEACAM1 specific
anti-pathogen vaccines are effective, the model must mimic the
human tissue specific pattern of CEACAM1 expression. Thus, our
approach was to generate transgenic mice that expressed the entire
human CEACAM1 gene rather than a cDNA for CEACAM1.
Although we attempted to generate several lines using BAC clones
that spanned different regions of chromosome 19 encoding the
CEACAM1 gene, only a single line that actually expressed the
protein was generated. Given the large number of variables that
affect both integration, expression, and transmission of a gene, the
reason for this result is unknown. Fortunately, the BAC2-12 line
obtained transmitted the transgene from the founder mouse to F1
and F2 generations and demonstrated the expected frequency for
heterozygotic expression in subsequent generations. Furthermore,
human specific splice forms were found in three major tissues
(liver, intestine and kidney) of known CEACAM1 expression and
tissue staining for human CEACAM1 demonstrated the expected
staining pattern, namely at the lumen of epithelial cells.
Both murine Ceacam1 and human CEACAM1 genes produce
multiple mRNA splice isoforms. Murine Ceacam1 generates
mRNAs having mainly 4 or 2 ectodomains with long or short
cytoplasmic domains. Indeed, the expected major splice isoforms
of murine Ceacam1 were found in the liver, intestine, and kidney of
both control and transgenic mice with a predominance of the -2S
isoform. The human CEACAM1 gene, in contrast, generates
mRNAs with different splice isoforms, namely -4L/S and -3L/S.
The expected human splice isoforms were observed in the BAC2-
12 transgenic line, with a predominance of -4S in the liver and -4L
in the intestine and kidney. Given the differences in murine and
human splice isoforms observed in the transgenic animals, we
Figure 9. Expression levels of murine and human CEACAM1 on spleen B and T cells of BAC2-12 transgenic and wild type mice.
Freshly isolated spleen cells (A) and Spleen cells treated with 1 mg/mL anti-CD3 and 2 mg/mL anti-CD28 mAb for three days (B) from TG or WT mice
were stained with either the anti-murine CEACAM1-PE or anti-human CEACAM1-PE and co-stained with anti-CD3-FITC and anti-B220-APC. Results
shown are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0010067.g009
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differentially spliced mRNA isoforms must be encoded in their
respective genes. A comparison of the gene sequences at putative
splice recognition sites may reveal which motifs are responsible for
the observed mRNA species and tissue specific splicing. Prelim-
inary studies on the human gene have begun to identify motifs
responsible for generation of the long and short cytoplasmic
domain splice forms [48]. The ratio of long and short CEACAM1
protein isoforms could critically affect cell function, since the short
form lacks the ITIM motif. While the significance of the number
of ectodomains is less well understood, the relative strength of cell-
cell adhesion may be affected [2].
Figure 10. Confocal analysis of transgenic mouse neutrophils undergoing binding of E. coli expressing recombinant Opa52 protein.
Panel 1. E. coli vector control or Opa52 phagocytosed by human neutrophils. A. Vector control E. coli (FITC labeled, green). B. Same as A, stained with
anti-human CEACAM1 mAb Alexa 555 labeled (red). C. Same as A, stained with DAPI (blue). D. Overlay of A–C on phase contrast image. Mag 300X. E.
Opa52 E. coli (FITC labeled, green). F. Same as E, stained with anti-human CEACAM1 Mab Alexa 555 labeled (red). G. Same as E, stained with DAPI
(blue). H. Overlay of E–G on phase contrast image. Mag 300X. Panel 2. E. coli vector control or Opa52 phagocytosed by neutrophils from transgenic
(A–D) or wild type (E–H) mice. A, E. Vector control E. coli (overlay with FITC, Alexa 555, and DAPI on phase contrast image). B, F. vector control E. coli
(FITC labeled, green). C, G. Opa52 E. coli. (overlay with FITC, Alexa 555, and DAPI on phase contrast image) D, H. Opa52 expressing E. coli (FITC
staining).
doi:10.1371/journal.pone.0010067.g010
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embryo at both the message and protein level has been studied
in detail [49]. Notably, murine CEACAM1 was found in the
developing gut, lung, and kidney epithelium. However, the
occurrence of two Ceacam genes in the mouse (and not in human)
complicates the picture, with the Ceacam2 gene mainly expressed in
the kidney and testis [37]. The high expression of CEACAM1 in
murine liver is striking and has been shown to regulate insulin
clearance [39]. The pattern of human CEACAM1 expression
closely mimics the mouse, with perhaps a caveat about the
differential expression of the two murine Ceacam genes in the
mouse. In our study of the human CEACAM1 transgenic mouse,
we were able to compare the staining of tissues for mouse and
human CEACAM1. Except for the kidney, the tissue staining
patterns and intensities were similar. In the case of the kidney, the
patterns were identical but the intensity of staining for human
CEACAM1 was greater than for murine CEACAM1. This result
probably reflects the higher expression of murine Ceacam2 (not
measured) over that of Ceacam1 in the kidney.
We were especially interested in the expression of the human
gene in the immune system. Murine CEACAM1 is known to be
expressed on spleen B-cells [50], serving as a receptor for the
murine hepatitis virus. Similarly, human CEACAM1 is expressed
on germinal center B-cells [17]. In the case of murine and human
T-cells, little or no surface expression is observed on resting T-
cells, but is highly expressed on activated T-cells [14,51]. As
expected, we found cell surface expression of both murine and
human CEACAM1 on splenic B-cells, but not on splenic T-cells.
Similar expression of murine and human CEACAM1 is expected
on the surface of neutrophils, whether from the bone marrow or
blood. Indeed, we found high levels of murine and human
CEACAM1 on neutrophils from either source. Based on this
preliminary analysis, it is likely that the CEACAM1 expression in
the immune system mimics that found in mouse and man.
The model system was further validated by examining the
binding of one of the Opa proteins found in Neisseria and known to
bind to human CEACAM1. In this example, we chose Opa52 a
Neisseria specific protein which had previously been shown to
confer binding to human neutrophils or to Hela cells transfected
with human CEACAM1 [8]. Since Neisseria may adhere to and be
phagocytosed by neutrophils via a variety of receptors, we chose to
demonstrate Opa52 binding using E. coli expressing this protein. As
expected, the Opa52 positive bacteria were bound in greater
numbers by the transgenic neutrophils than the Opa52 negative
bacteria. Thus, the model appears to mimic what is observed with
human neutrophils using Opa52 positive Neisseria. Furthermore,
the model should allow investigation into insulin clearance,
vasculogenesis, lumen formation, and other functions ascribed to
human CEACAM1 in a physiological setting.
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